Jefferies Flags GSK's Oncology Pipeline as Major Value Driver with Four Near-Term Catalysts in 2026
核心洞察
Jefferies (搜索) reaffirmed its buy rating and 2,500p price target on GSK following a fireside chat with GSK's oncology leadership at the bank's New York healthcare conference.
GSK plans to present new datasets for its B7H3 antibody-drug conjugate (搜索) at a major oncology conference in the second half of 2026, likely ESMO, with additional phase III trials expected soon.
Management highlighted that IDRx-42 for gastrointestinal stromal tumors (搜索) shows a notably lower grade 3 adverse event rate than competing combination approaches.
Jefferies (搜索) has identified four near-term catalysts in GSK's oncology pipeline that could serve as major value drivers for the pharmaceutical company, following a fireside chat with GSK's global head of oncology and research and development at the bank's New York healthcare conference. The investment bank reaffirmed its buy rating and 2,500p price target on GSK, which is currently trading at 1,872p on the London Stock Exchange.
B7H3 Antibody-Drug Conjugate (搜索) Data on the Horizon
GSK plans to present additional datasets for its B7H3 antibody-drug conjugate (搜索) (ADC) at a major oncology conference in the second half of 2026. Jefferies (搜索) analysts believe the venue is likely to be ESMO, the European Society for Medical Oncology's annual meeting. The B7H3 (搜索)-targeted therapy is designed to deliver toxic payloads directly to tumor cells, and management views this asset as equally important to its B7H4 (搜索) programme.
While the B7H4 (搜索) programme is focused on gynecological cancers, particularly ovarian and endometrial malignancies, the B7H3 (搜索) ADC has a broader expression profile spanning thoracic, gastrointestinal, prostate, and sarcoma tumors. Several additional phase III trials for B7H3 are expected to be disclosed over the coming months, signaling GSK's commitment to advancing this asset across multiple indications.
IDRx-42 Shows Favorable Safety Profile in GIST
On IDRx-42, GSK's treatment for gastrointestinal stromal tumors (搜索) (GIST), management highlighted that the grade 3 adverse event rate is notably lower than competing combination approaches. This safety advantage was underscored following positive data presented at the ASCO oncology conference. GSK indicated it is doing what it can to accelerate the phase III first-line programme for IDRx-42, reflecting confidence in the asset's competitive positioning.
Blenrep Modeling Data Sparks Renewed Interest
Jefferies (搜索) also flagged renewed interest in Blenrep, GSK's multiple myeloma (搜索) treatment, after modeling data presented at the European Myeloma Network suggested that median progression-free survival in a triplet combination could reach 100 months at the DREAMM-10 trial dose. This compares favorably to the 90 months seen with the currently approved quadruplet regimen, potentially positioning Blenrep as a compelling option in the multiple myeloma treatment landscape.
AI, Digital Pathology, and External Innovation
Artificial intelligence and digital pathology were described as fundamental pillars of GSK's research approach. The company's 2025 acquisition of CELLphenomics (搜索), which specializes in organoid technology to better understand tumor biology, exemplifies this strategic focus. Additionally, GSK management noted that external mergers and acquisitions will always be necessary to complement internal research and development, flagging a growing pipeline of innovation from Asia as a particular area of interest.
Jefferies (搜索) concluded that GSK's oncology division remains on track to make a significant contribution to the company's sales by 2031 and beyond, with the four near-term catalysts providing multiple opportunities for value creation in the near future.